Investors Seeking Value Creation Fully Subscribe ExchangeRight's Third Value-Add Portfolio
VAP 3 has significantly outperformed pro forma underwriting from inception to date. ExchangeRight's strategy focuses on increasing occupancy across the portfolio's shopping centers and securing favorable renewals with existing tenants. Positive variances in both total income and the company's Asset Management team's ability to mitigate operating expenses led to actual Net Operating Income surpassing projections by 12.2% through the first 10 months of VAP 3's fiscal year 1.
VAP 3 is a diversified portfolio of in-line and outparcel retail tenants shadow-anchored by long-term net-leased and strong-performing grocery and national retail companies. The portfolio features 8 in-line shopping centers diversified across 7 states with more than 43 unique tenants, exhibiting in-place cash flow with the potential to preserve capital and provide long-term upside via strategic leasing initiatives and tenant improvements. The portfolio's centers collectively span 95,914 square feet and are shadow-anchored by historically recession-resilient companies, including UnityPoint Health, ShopRite, Giant Eagle, and Food Lion. VAP 3 intends to provide investors with enhanced value and multiple exit options through ExchangeRight's aggregation strategy.
About ExchangeRight
ExchangeRight and its affiliates' vertically integrated platform features more than
Media Contact
Senior Media Relations Officer
[email protected]
(626) 773-3448
View original content to download multimedia:https://www.prnewswire.com/news-releases/investors-seeking-value-creation-fully-subscribe-exchangerights-third-value-add-portfolio-302162575.html
SOURCE ExchangeRight
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BilibiliWorld 2026 Becomes Asia's Largest ACGN Convention with 400,000 Attendee Visits
- Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference® (AAIC®) 2026
- ALZpath Demonstrates Global Clinical Impact at AAIC 2026, with Proprietary pTau217 Antibody Anchoring 86 Presentations Demonstrating Clinical and Diagnostic Value Across the Translational Pipeline
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share